Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00032773
Status:
TERMINATED
Last Update Posted:
2020-10-23
First Post:
2002-04-02
Brief Title:
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
Sponsor:
Astex Pharmaceuticals Inc
Organization:
Astex Pharmaceuticals Inc
Study Overview
Official Title:
A Sequentially Adaptive Open Label Dose-finding Phase III Trial of Pentostatin in the Treatment of Steroid-refractory Acute Graft Versus Host Disease aGvHD
Status:
TERMINATED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20 or more of patients while producing treatment failure defines as death grade 34 toxicity or progressive disease in 40 or less of patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NIP-010 | None | None | None |